Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.

Hande KızılocakElizabeth Marquez-CasasChoo Phei WeeJemily MalvarRoxana CarmonaGuy Aaron Young

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Due to the known thrombotic complications when emicizumab is used in conjunction with aPCC, there has been a large-scale abandonment of the use of aPCC in patients on emicizumab. However, it is possible that aPCC can be used safely with emicizumab albeit with lower doses than are typically prescribed. It would be important to test this hypothesis in a clinical study.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
patient reported outcomes
high throughput